期刊
BRITISH JOURNAL OF CANCER
卷 105, 期 5, 页码 628-639出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2011.240
关键词
assessment; novel radiosensitisers; early; preclinical; clinical
类别
资金
- MRC [G0500366, G0700730, G0800808] Funding Source: UKRI
- Cancer Research UK [10588, 11335] Funding Source: researchfish
- Medical Research Council [G0800808, G0700730, G0500366] Funding Source: researchfish
- Cancer Research UK [10588, 11335] Funding Source: Medline
- Medical Research Council [G0800808, G0700730, G0500366] Funding Source: Medline
There is a growing appreciation of the potential value of combining novel molecularly-targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have the potential to improve locoregional disease control and cure rates across a diverse range of tumour types. In this report, we outline a rational framework for developing novel drug-radiation combinations. In doing so, we make recommendations regarding the core preclinical data sets that are required to serve as justification for studies in humans and describe potential clinical trial designs that may be adopted by investigators.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据